Canada's health regulator has approved Novo Nordisk's weight loss drug Wegovy to reduce the risk of nonfatal heart attack or ...

Shares in Amgen fell on Tuesday after they announced the results of a trial for their weight loss drug MariTide.

The Biden administration has proposed a new rule to “significantly” expand coverage of anti-obesity medications for Americans ...

A new rule proposed by CMS presents alterations to the Medicare program, including expanded coverage for anti-obesity ...

The Department of Health and Human Services seeks to expand when Medicare and Medicaid can cover anti-obesity drugs, such as ...

With expected sales for GLP1Rs in obesity estimated to surpass $126 billion by 2030, this drug category presents a lucrative ...

Wegovy is also approved in the U.K. and the U.S. to lower the risk of serious heart problems or strokes in overweight and ...

Study subjects taking the company’s MariTide lost about 20% of their weight in the 52-week trial.

That increased convenience will have to be accompanied by weight loss that is at least as effective as its rivals, and Amgen ...

The CMS estimated that coverage of the weight-loss drugs will cost the federal government about $25 billion for Medicare and ...

Patrick Smith, President of Drug Development Solutions, Certara. Inflation and the Covid-19 pandemic have put pharmaceutical ...